AbbVie forms AI drug discovery partnership with Iambic, which is preparing a stock market listing

Sep 21, 2026 · Issue 8 · 12 sources, 15 articles

AbbVie has entered a collaboration with AI-driven drug discovery company Iambic Therapeutics. Nvidia-backed Iambic has also applied for a Nasdaq listing and would put the proceeds toward developing cancer drugs.

Who is affected and how

pharmaceuticals

Big pharma partnerships with AI biotechs reinforce the pattern of outsourcing early-stage research, so companies should review their own partnership strategy.

Narrative: AI is rewriting drug development

Sources

• AbbVie Forms Ai-Powered Drug Discovery Partnership with Iambic | PharmExecpharmaceutical executive · Sep 21, 2026
• Iambic, AbbVie partner on AI drug discoverymobihealthnews · Sep 21, 2026
• AbbVie partners with Iambic on AI drug discovery collaboration By Investing.cominvesting.com uk · Sep 21, 2026
• Pharmaceutical Executive Daily: AbbVie Forms Ai-Powered Drug Discovery Partnership with Iambic | PharmExecpharmexec.com · Sep 21, 2026
• AbbVie and Iambic: Partnering on AI-Powered Drug Discoveryhealthcare digital · Sep 22, 2026
• AbbVie Partners With Iambic to Accelerate AI-Driven Drug Discoveryaim media house · Sep 22, 2026
• AbbVie and Iambic Partner to Accelerate AI-Driven Small-Molecule Drug Discovery - Pharmacallypharmacally.com · Sep 22, 2026
• AbbVie, Iambic Partner on AI-Driven Drug Discoverydigitalhealthnews.com · Sep 23, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.